{"id":610345,"date":"2026-08-26T13:57:29","date_gmt":"2026-08-26T13:57:29","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/610345\/nasdaq-30s-vivs-igc-rime-aixi-stocks-now.html"},"modified":"2026-08-26T13:57:29","modified_gmt":"2026-08-26T13:57:29","slug":"nasdaq-30s-vivs-igc-rime-aixi-stocks-now","status":"publish","type":"post","link":"https:\/\/www.pennsylvania-magazine.com\/news\/story\/610345\/nasdaq-30s-vivs-igc-rime-aixi-stocks-now.html","title":{"rendered":"Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now"},"content":{"rendered":"
\"Nasdaq<\/a><\/div>\n

August 26, 2026<\/strong> — Investor attention is building around several lower-priced small-cap stocks trading near the $0.30 range<\/strong>, including VivoSim Labs, Inc. (NASDAQ: VIVS), IGC Pharma, Inc. (NYSE: IGC), Algorhythm Holdings, Inc. (NASDAQ: RIME)<\/strong> and Xiao-I Corporation (NASDAQ: AIXI), as company-specific catalysts across AI, biotechnology, drug development and logistics technology<\/strong> drive trading interest.VivoSim Labs (NASDAQ: VIVS) — AI Drug Toxicity and FDA NAM Momentum<\/p>\n

VivoSim Labs (NASDAQ: VIVS) $5M Eli Lilly (NYSE: LLY) Milestone as Drug Advances to Human Trials<\/p>\n

VivoSim Labs, Inc. (NASDAQ: VIVS)<\/strong> is gaining investor attention following a research report highlighting its AI-powered drug toxicity platform and growing FDA momentum behind human-relevant New Approach Methodologies (NAMs)<\/strong>. The company’s NAMkind™ 3D human liver and intestinal tissue models have reported approximately 91% predictive accuracy for liver toxicity<\/strong> and up to 96% accuracy predicting drug-induced diarrhea<\/strong>, while commercialization is expanding through initial China contracts and APAC distribution relationships.<\/p>\n

VivoSim has reiterated guidance for 500%+ fiscal 2027 revenue growth<\/strong> from its NAM-based contract research business and recently reported approximately $10.1 million in cash<\/strong>, supported in part by a $5 million milestone payment from Eli Lilly and Company (NYSE: LLY)<\/strong> related to a previously divested inflammatory bowel disease program. VivoSim has stated it remains eligible for up to an additional $45 million in potential milestone payments<\/strong> if specified development and commercial milestones are achieved. See Complete VivoSim Labs Research Report<\/strong><\/a><\/p>\n

IGC Pharma (NYSE: IGC) — Alzheimer’s Catalyst Approaches<\/p>\n

IGC Pharma, Inc. (NYSE: IGC)<\/strong> is approaching a potentially important Alzheimer’s disease clinical catalyst<\/strong> after reporting Q2 2026 results that beat Street estimates and advancing its Phase 2 IGC-AD1 Alzheimer’s trial<\/strong> toward enrollment completion, with topline results expected in Q4 2026<\/strong>.<\/p>\n

The company is also expanding its AI-enabled drug discovery capabilities<\/strong>. Management recently converted approximately $1.15 million of company obligations into more than 4.27 million IGC shares at $0.27 per share<\/strong>. Investor interest has strengthened, with shares moving from approximately $0.245 to as high as $0.308 during August<\/strong>, representing a roughly 25.7% increase<\/strong>, accompanied by elevated trading volume.<\/p>\n

Algorhythm Holdings (NASDAQ: RIME) — Strategic Alternatives for SemiCab AI Logistics<\/p>\n

Algorhythm Holdings, Inc. (NASDAQ: RIME)<\/strong> is an AI technology company whose SemiCab<\/strong> platform uses artificial intelligence to optimize freight networks, reduce empty truck miles, lower transportation costs and improve logistics efficiency for shippers and carriers.<\/p>\n

Adding a new potential catalyst, Algorhythm announced on August 25, 2026<\/strong> that it is pursuing a potential sale and other strategic alternatives for its SemiCab AI logistics business<\/strong>. The development could place additional investor focus on the potential value of SemiCab’s technology, customer relationships and logistics platform as the company evaluates its strategic direction.<\/p>\n

Xiao-I (NASDAQ: AIXI) — Artificial Intelligence and Cognitive Intelligence<\/p>\n

Xiao-I Corporation (NASDAQ: AIXI)<\/strong> is an artificial intelligence company focused on cognitive intelligence technologies and enterprise AI solutions<\/strong>. Its technology portfolio spans natural language processing, voice and image recognition, machine learning and affective computing, with applications designed to help enterprises automate operations and advance digital transformation.<\/p>\n

With investor interest remaining elevated across the broader AI software and artificial intelligence sector<\/strong>, AIXI provides traders with exposure to an established developer of proprietary cognitive intelligence technologies serving a range of business applications.<\/p>\n

With VIVS targeting AI-powered human drug toxicity testing, AIXI focused on enterprise cognitive intelligence, IGC approaching Alzheimer’s clinical data and RIME evaluating strategic alternatives for its AI logistics business<\/strong>, the four lower-priced stocks represent distinct company-specific catalysts for small-cap investors and active traders to watch.<\/p>\n

About the Companies<\/p>\n

VivoSim Labs, Inc. (NASDAQ: VIVS)<\/strong> provides pharmaceutical and biotechnology companies with 3D human liver and intestinal tissue models for drug testing and toxicology using New Approach Methodologies.<\/p>\n

Xiao-I Corporation (NASDAQ: AIXI)<\/strong> develops cognitive intelligence and artificial intelligence technologies for enterprise applications, including natural language processing, machine learning, voice and image recognition.<\/p>\n

IGC Pharma, Inc. (NYSE: IGC)<\/strong> is a clinical-stage biotechnology company developing therapeutics and AI-enabled technologies targeting Alzheimer’s disease and other neurodegenerative conditions.<\/p>\n

Algorhythm Holdings, Inc. (NASDAQ: RIME)<\/strong> is an AI technology company whose SemiCab platform applies artificial intelligence to freight and transportation-network optimization.<\/p>\n

About The Street Reports<\/p>\n

The Street Reports (TSR)<\/strong> is a financial media platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.<\/p>\n

 <\/p>\n

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> The Street Reports<\/a>
Contact Person:<\/strong> Editor
Email:<\/strong> Send Email<\/a>
Country:<\/strong> United States
Website:<\/strong> http:\/\/www.thestreetreports.com<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

August 26, 2026 — Investor attention is building around several lower-priced small-cap stocks trading near the $0.30 range, including VivoSim Labs, Inc. (NASDAQ: VIVS), IGC Pharma, Inc. (NYSE: IGC), Algorhythm<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts\/610345"}],"collection":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/comments?post=610345"}],"version-history":[{"count":0,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts\/610345\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/media?parent=610345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/categories?post=610345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/tags?post=610345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}